Argent Capital Management LLC Purchases 4,950 Shares of Supernus Pharmaceuticals Inc (SUPN)

Argent Capital Management LLC increased its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 5.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,950 shares of the specialty pharmaceutical company’s stock after buying an additional 4,950 shares during the period. Argent Capital Management LLC owned approximately 0.18% of Supernus Pharmaceuticals worth $2,784,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of SUPN. State of Alaska Department of Revenue increased its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the last quarter. Texas Permanent School Fund increased its stake in shares of Supernus Pharmaceuticals by 0.5% in the first quarter. Texas Permanent School Fund now owns 36,288 shares of the specialty pharmaceutical company’s stock valued at $1,136,000 after buying an additional 178 shares during the last quarter. Picton Mahoney Asset Management increased its stake in shares of Supernus Pharmaceuticals by 1.4% in the third quarter. Picton Mahoney Asset Management now owns 15,000 shares of the specialty pharmaceutical company’s stock valued at $371,000 after buying an additional 200 shares during the last quarter. Suntrust Banks Inc. increased its stake in shares of Supernus Pharmaceuticals by 1.8% in the first quarter. Suntrust Banks Inc. now owns 19,913 shares of the specialty pharmaceutical company’s stock valued at $622,000 after buying an additional 343 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of Supernus Pharmaceuticals by 0.5% in the fourth quarter. New York State Teachers Retirement System now owns 77,035 shares of the specialty pharmaceutical company’s stock valued at $1,945,000 after buying an additional 400 shares during the last quarter. 92.17% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals Inc (SUPN) traded down 1.28% on Friday, hitting $38.65. The company had a trading volume of 1,266,125 shares. The stock has a market cap of $1.94 billion, a P/E ratio of 20.79 and a beta of 1.76. Supernus Pharmaceuticals Inc has a 12-month low of $17.25 and a 12-month high of $41.35. The firm’s 50 day moving average price is $35.55 and its 200 day moving average price is $29.14.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The business had revenue of $57.58 million during the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a net margin of 17.88% and a return on equity of 20.76%. Equities analysts predict that Supernus Pharmaceuticals Inc will post $1.08 earnings per share for the current fiscal year.

WARNING: This news story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/06/16/argent-capital-management-llc-purchases-4950-shares-of-supernus-pharmaceuticals-inc-supn-updated-updated.html.

Several brokerages have recently weighed in on SUPN. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Jefferies Group LLC boosted their price target on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Piper Jaffray Companies upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $30.00 to $44.00 in a research note on Thursday, June 1st. Cowen and Company boosted their price target on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, May 11th. Finally, Zacks Investment Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $33.43.

In related news, CFO Gregory S. Patrick sold 54,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $32.37, for a total transaction of $1,747,980.00. Following the sale, the chief financial officer now directly owns 54,221 shares of the company’s stock, valued at $1,755,133.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 5,500 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the sale, the vice president now directly owns 43,887 shares in the company, valued at $1,531,656.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 83,806 shares of company stock worth $2,813,038. 6.70% of the stock is currently owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply